Literature DB >> 15285038

Analysis of multiple factors of postsurgical gastroparesis syndrome after pancreaticoduodenectomy and cryotherapy for pancreatic cancer.

Ke Dong1, Bo Li, Quan-Lin Guan, Tao Huang.   

Abstract

AIM: To explore the etiology, pathogenesis, diagnosis, and treatment of postsurgical gastroparesis syndrome (PGS) after pancreatic cancer cryotherapy (PCC) or pancreatico-duodenectomy (PD), and to analyze the correlation between the multiple factors and PGS caused by the operations.
METHODS: Clinical data of 210 patients undergoing PD and 46 undergoing PCC were analyzed retrospectively.
RESULTS: There were 31 (67%, 31/46) patients suffering PGS in PCC group, including 29 with pancreatic head and uncinate tumors and 2 with pancreatic body and tail tumors. Ten patients (4.8%, 10/210) developed PGS in PD group, which had a significantly lower incidence of PGS than PCC group (chi= 145, P<0.001). In PCC group, 9 patients with PGS were managed with non-operative treatment (drugs, diet, nasogastric suction, etc.), and one received reoperation at the 16th day, but the symptoms were not relieved. In PD group, all the patients with PGS were managed with non-operative treatment. The PGS in patients undergoing PCC had close association with PCC, tumor location, but not with age, gender, obstructive jaundice, hypoproteinemia, preoperative gastric outlet obstruction and the type and number of gastric biliary tract operations. The mechanisms of PGS caused by PD were similar to those of PGS following gastrectomy. The damage to interstitial cells of Cajal might play a role in the pathogenesis of PGS after PCC, for which multiple factors were possibly responsible, including ischemic and neural injury to the antropyloric muscle and the duodenum after freezing of the pancreatico-duodenal regions or reduced circulating levels of motilin.
CONCLUSION: PGS after PCC or PD is induced by multiple factors and the exact mechanisms, which might differ between these two operations, remain unknown. Radiography of the upper gastrointestinal tract and gastroscopy are main diagnostic modalities for PGS. Non-operative treatments are effective for PGS, and reoperation should be avoided in patients with PGS caused by PCC.

Entities:  

Mesh:

Year:  2004        PMID: 15285038      PMCID: PMC4576306          DOI: 10.3748/wjg.v10.i16.2434

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  19 in total

Review 1.  Electrogastrography: a non-invasive measurement of gastric function.

Authors:  P M Lawlor; J A McCullough; P J Byrne; J V Reynolds
Journal:  Ir J Med Sci       Date:  2001 Apr-Jun       Impact factor: 1.568

2.  Pancreatic head resection with and without preservation of the duodenum: different postoperative gastric motility.

Authors:  G Naritomi; M Tanaka; H Matsunaga; K Yokohata; Y Ogawa; K Chijiiwa; K Yamaguchi
Journal:  Surgery       Date:  1996-11       Impact factor: 3.982

3.  Manometric evidence of improved early gastric stasis by erythromycin after pylorus-preserving pancreatoduodenectomy.

Authors:  H Matsunaga; M Tanaka; S Takahata; Y Ogawa; G Naritomi; K Yokohata; K Yamaguchi; K Chijiiwa
Journal:  World J Surg       Date:  2000-10       Impact factor: 3.352

4.  Cryoablation of unresectable pancreatic cancer.

Authors:  Stephen J Kovach; Richard J Hendrickson; Charles R Cappadona; C Max Schmidt; Kara Groen; Leonidas G Koniaris; James V Sitzmann
Journal:  Surgery       Date:  2002-04       Impact factor: 3.982

Review 5.  Treatment of gastroparesis with electrical stimulation.

Authors:  Zhiyue Lin; Jameson Forster; Irene Sarosiek; Richard W McCallum
Journal:  Dig Dis Sci       Date:  2003-05       Impact factor: 3.199

6.  Long-term outcome after gastrectomy for intractable diabetic gastroparesis.

Authors:  P J Watkins; M S Buxton-Thomas; E R Howard
Journal:  Diabet Med       Date:  2003-01       Impact factor: 4.359

Review 7.  Gastric atony and the Roux syndrome.

Authors:  B D Schirmer
Journal:  Gastroenterol Clin North Am       Date:  1994-06       Impact factor: 3.806

8.  Glucose control is not improved by accelerating gastric emptying in patients with type 1 diabetes mellitus and gastroparesis. a pilot study with cisapride as a model drug.

Authors:  R Lehmann; R A Honegger; C Feinle; M Fried; G A Spinas; W Schwizer
Journal:  Exp Clin Endocrinol Diabetes       Date:  2003-08       Impact factor: 2.949

9.  Severe idiopathic gastroparesis due to neuronal and interstitial cells of Cajal degeneration: pathological findings and management.

Authors:  N Zárate; F Mearin; X-Y Wang; B Hewlett; J D Huizinga; J-R Malagelada
Journal:  Gut       Date:  2003-07       Impact factor: 23.059

10.  Gastric electrical stimulation for gastroparesis improves nutritional parameters at short, intermediate, and long-term follow-up.

Authors:  Thomas Abell; Jean Lou; Mumtaz Tabbaa; Oscar Batista; Scott Malinowski; Amar Al-Juburi
Journal:  JPEN J Parenter Enteral Nutr       Date:  2003 Jul-Aug       Impact factor: 4.016

View more
  4 in total

1.  Enteral nutrition reduces delayed gastric emptying after standard pancreaticoduodenectomy with child reconstruction.

Authors:  Michel Rayar; Laurent Sulpice; Bernard Meunier; Karim Boudjema
Journal:  J Gastrointest Surg       Date:  2012-01-19       Impact factor: 3.452

2.  Results of completion gastrectomies in 44 patients with postsurgical gastric atony.

Authors:  James E Speicher; Richard C Thirlby; Joseph Burggraaf; Christopher Kelly; Sarah Levasseur
Journal:  J Gastrointest Surg       Date:  2009-02-18       Impact factor: 3.452

Review 3.  Da-Cheng-Qi Decoction Combined with Conventional Treatment for Treating Postsurgical Gastrointestinal Dysfunction.

Authors:  Wei Jin; Qingjie Li; Xiaoqiong Luo; Juan Zhong; Yang Song; Yiwei Li
Journal:  Evid Based Complement Alternat Med       Date:  2017-05-15       Impact factor: 2.629

4.  The quantification and assessment of depression and anxiety in patients with postoperative gastroparesis syndrome.

Authors:  Li-Juan Zheng; Jia-Chi Ma; Dong Fang; Li-Gang Wu; Zhen-Qiang Gong; Jian-Bo Qi; Xiao-Dan Zhao; Jian-Bo Du; Pei-Lan Ma
Journal:  Ther Clin Risk Manag       Date:  2018-03-15       Impact factor: 2.423

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.